Conv. Plasma
Nigella Sativa

All azvudine studies
Meta analysis
study COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, day 28 35% Improvement Relative Risk Mortality, day 14 52% Mortality, day 7 87% Azvudine for COVID-19  Zhong et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? Retrospective 2,863 patients in China (December 2022 - March 2023) No significant difference in mortality Zhong et al., Research Square, April 2024 Favors azvudine Favors control

Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study

Zhong et al., Research Square, doi:10.21203/
Apr 2024  
  Source   PDF   All   Meta
Azvudine for COVID-19
41st treatment shown to reduce risk in July 2023
*, now known with p = 0.00014 from 18 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 2,862 hospitalized COVID-19 patients in China showing lower mortality with azvudine treatment.
risk of death, 35.0% lower, HR 0.65, p = 0.048, treatment 1,490, control 1,373, propensity score weighting, day 28.
risk of death, 52.0% lower, HR 0.48, p = 0.001, treatment 1,490, control 1,373, propensity score weighting, day 14.
risk of death, 87.0% lower, HR 0.13, p = 0.001, treatment 1,490, control 1,373, propensity score weighting, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhong et al., 1 Apr 2024, retrospective, China, preprint, 7 authors, study period 1 December, 2022 - 31 March, 2023.
This PaperAzvudineAll
Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study
Zhen Zhong, Xiao-Feng Liu, Xiao-Zhong Zhou, Jia-Ning Zhong, Li-Cheng Zhou, Rong Li, Xian-Fa Liu
Background: Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, e cacy, and target populations of these novel therapeutic drugs are necessary. Hence, this study aimed to investigate the effectiveness of azvudine in hospitalized patients with COVID-19. Methods: We conducted a retrospective cohort study of patients with COVID-19 admitted to our hospital from December 1, 2022, to March 31, 2023. Patients were divided into retrospective cohorts receiving azvudine antiviral therapy and standard treatment, and were followed-up for up to 28 days. Results: Prior to data processing, azvudine treatment was associated with reduced mortality rates at 7 days (1.09/1000 persons vs.5.06/1000 persons, p<0.001)and 14 days (3.35/1000 persons vs. 5.65/1000 persons, p=0.001). After propensity score matching, a decrease in mortality rates at 7 days (0.08/1000 persons vs.6.29/1000 persons, p<0.001), 14 days (3.42/1000 persons vs. 7.26/1000 persons, p<0.001), and 28 days (4.33/1000 persons vs. 7.29/1000 persons, p=0.003) were observed following azvudine treatment. After inverse probability of treatment weighting adjustment, the results were consistent with propensity score matching. In the clinical subgroup analysis, for hospitalized severe and critical patients with COVID-19, azvudine treatment intervention signi cantly reduced patient mortality rates. Conclusions: The study suggests that in hospitalized patients with COVID-19, azvudine treatment signi cantly reduces patient mortality rates in hospitalized COVID-19 infections, wherein the effects are more pronounced in severe and critical patients.
Declarations Ethics approval and consent to participate was no direct involvement in the conception, design, or implementation of this study. The requirement for patient consent was waived for this retrospective study, which utilized data from electronic medical records. This study was approved by the Ethics Committee of the First A liated Hospital of the Gannan Medical University Hospital (LLSL-2024065). Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Author Contributions Statement XianfaL JZ designed the experiments. XiaoL was responsible for clinical assessment of patients. LZ, XZ, LR,and ZZ collected the data. JZ was responsible for data management. JZ and ZZ conducted the statistical analysis. This article was written by ZZ, and reviewed by XianfaL. All the authors have reviewed and approved of the nal manuscript. Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. azvudineattachment.docx
Bertuccio, The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study, Infection, doi:10.1007/s15010-023-02028-5
Deng, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, Journal of medical virology, doi:10.1002/jmv.28756
Deng, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, Journal of medical virology, doi:10.1002/jmv.28756
Fayzullina, FNC: An Advanced Anticancer Therapeutic or Just an Underdog?, Frontiers in oncology, doi:10.3389/fonc.2022.820647
Gao, Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19, The Journal of infection, doi:10.1016/j.jinf.2023.03.023
Gentile, Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study, Vaccines, doi:10.3390/vaccines10101731
Gentile, Scotto, Schiano Moriello, Pinchera, Villari et al., Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a reallife study, Vaccines, doi:10.3390/vaccines10101731
Lui, Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong, JAMA network open, doi:10.1001/jamanetworkopen.2023.14393
Morris, Lee, Nirmatrelvir for Nonhospitalized Adults with Covid-19, The New England journal of medicine, doi:10.1056/NEJMc2206277
Shen, Xiao, Sun, Li, Wu et al., Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study, medRxiv, doi:10.1101/2023.01.23.23284899
Wang, Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study, EClinicalMedicine, doi:10.1016/j.eclinm.2024.102468
Wong, Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with con rmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet, doi:10.1016/S0140-6736(22)01586-0
Xie, Molnupiravir and risk of post-acute sequelae of covid-19: cohort study, BMJ (Clinical research, doi:10.1136/bmj-2022-074572
Yu, Chang, The rst Chinese oral anti-COVID-19 drug Azvudine launched, Innovation, doi:10.1016/j.xinn.2022.100321
Zhang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal transduction and targeted therapy, doi:10.1038/s41392-021-00835-6
Zhou, Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-tosevere COVID-19: Emulation of a randomized target trial, Journal of medical virology, doi:10.1002/jmv.29318
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop